Skip to content
Screener

BioCryst Pharmaceuticals BCRX Compensation and benefits

Compensation and benefits at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$45.6M+53.6%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$17.7M+45.5%

Segments

By segment

See full
Reportable Segment$14.69M-31.0%

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.38B+31.6%
Enterprise value$2.63B+33.4%
P/S2.5×-0.7×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Other non-program specific and indirect costs7,0446,74314,46313,289
Sales and marketing (excluding stock-based compensation)33,94745,58976,90093,259
General and administrative (excluding stock-based compensation)20,81029,81763,20351,776
Stock-based compensation14,69221,30430,71942,672
Interest income(2,434)(2,516)(4,690)(5,540)
Interest expense21,71221,58241,49145,076
Foreign currency (gains) losses(27)6319862
Loss on extinguishment of debt4,1714,171

Item 1. Financial Statements (Unaudited):

FAQ

What is BioCryst Pharmaceuticals's compensation and benefits?
BioCryst Pharmaceuticals (BCRX) reported compensation and benefits of $14.69M in Q2 2026.
How has BioCryst Pharmaceuticals's compensation and benefits changed year-over-year?
BioCryst Pharmaceuticals's compensation and benefits decreased by 31.0% year-over-year, from $21.3M to $14.69M.
What is the long-term trend for BioCryst Pharmaceuticals's compensation and benefits?
Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's compensation and benefits has grown at a 25.2% compound annual growth rate (CAGR), from $34.64M to $85.07M.
What does compensation and benefits mean?
Total employee-related costs including salaries, wages, bonuses, commissions, stock-based compensation, health insurance, retirement contributions, and payroll taxes.

Ask your AI about BioCryst Pharmaceuticals's compensation and benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude